Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

Special Features of Adaptive Immunity

Special Features of Adaptive Immunity

The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Adrenergic Receptors: ɑ Subtype

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Small Macule on the Eyelid: Stork Bite or Something Else?

Actas dermo-sifiliograficas·2019

Same author

Perifollicular Palpable Purpura as the Initial Manifestation of HIV Infection.

Actas dermo-sifiliograficas·2017

Same author

Unusual Interface Dermatoses Distributed Along Blaschko's Lines in Adult Patients.

The American Journal of dermatopathology·2017

Same author

New-Onset Mass in an Immunosuppressed Patient.

Actas dermo-sifiliograficas·2015

Same author

CHILD syndrome with minimal limb abnormalities.

Journal of the European Academy of Dermatology and Venereology : JEADV·2015

Same author

Psoriasiform exfoliative erythroderma induced by golimumab.

Clinical and experimental dermatology·2014

Search research articles

Related Experiment Video

Updated: Jul 3, 2026

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Published on: September 20, 2018

[What is special about adalimumab?].

I Rodríguez-Blanco¹, J Toribio

¹Servicio de Dermatología. Complejo Hospitalario Universitario. Facultad de Medicina. Santiago de Compostela. España.

Actas Dermo-Sifiliograficas

|August 19, 2008

Summary

Adalimumab, a fully human anti-tumor necrosis factor (TNF-alpha) antibody, effectively treats autoimmune conditions like rheumatoid arthritis. It demonstrates a favorable safety profile, comparable to other TNF-alpha inhibitors.

More Related Videos

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

Related Experiment Videos

Last Updated: Jul 3, 2026

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Published on: September 20, 2018

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

Area of Science:

Immunology
Pharmacology
Rheumatology

Background:

Adalimumab is a fully human monoclonal antibody targeting tumor necrosis factor-alpha (TNF-alpha).
TNF-alpha plays a key role in inflammatory and immune responses.
Its modulation is crucial for treating various autoimmune and inflammatory diseases.

Purpose of the Study:

To review the efficacy and safety of adalimumab in treating autoimmune diseases.
To highlight the specific characteristics of adalimumab as an anti-TNF-alpha therapy.
To consolidate accumulated clinical experience with adalimumab.

Main Methods:

Review of clinical trial data assessing adalimumab efficacy.
Analysis of safety profiles and adverse effects from clinical studies.
Consolidation of experience in rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease.

Main Results:

Adalimumab demonstrates efficacy in treating rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease.
Therapeutic effects of adalimumab can be observed as early as one week.
Adalimumab exhibits a safety profile similar to other anti-TNF-alpha agents.

Conclusions:

Adalimumab is a safe and effective therapeutic option for multiple inflammatory conditions.
Its mechanism of action involves binding and neutralizing TNF-alpha.
Clinical experience supports its use in managing autoimmune diseases with a predictable safety profile.